EUVIMEDScopri EUVIMED
Multizentrische StudieOpen access · CC BY-NC 4.0

Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease

Lesley A Patmore iD, Ivana Carey, Jordan J Feld, Willem P Brouwer iD, Keyur Patel iD, Maria Buti iD, Pieter Honkoop, Douwe F Postma, Hans Blokzijl, Özgur M Koc, Eva van Oorschot, Kosh Agarwal and 11 more

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70360 ↗

At a glance

Multizentrische Studie in Alimentary Pharmacology & Therapeutics, 2026. Written by Lesley A Patmore and 22 co-authors. Institution: Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, the Netherlands. Major MEDLINE topics: Carcinoma, Hepatocellular, Hepatitis B, Chronic, Liver Neoplasms, Fatty Liver. Cited 8 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Stichting voor Lever- en Maag-Darm Onderzoek, Gilead Sciences.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Introduction

Metabolic dysfunction and metabolic dysfunction‐associated steatotic liver disease (MASLD) are associated with an increased risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to study risk factors for HCC and to assess the performance of the PAGE‐B score in this population.

Methods

We included CHB patients with ≥ 1 metabolic comorbidity from nine centres. Steatosis was diagnosed by ultrasound, CAP, or histology. Risk factors were analysed by Cox regression, and the performance of the PAGE‐B score was assessed in the overall population and across relevant subgroups.

Results

We included 1922 patients. 1730 (90.0%) were overweight, 434 (22.6%) had hypertension, 254 (13.2%) dyslipidemia, 230 (12.0%) diabetes and 732 (38.1%) MASLD. Presence of cirrhosis, older age, lower platelets and lower albumin were independent risk factors for HCC. The 5‐year HCC risk was 0.1%/2.0%/12.4% patients with low/intermediate/high PAGE‐B scores ( p < 0.001). Consistent results were obtained in patients with MASLD (0/2.8/11.1% for low, intermediate and high PAGE‐B scores ( p < 0.001)). PAGE‐B stratified risk in patients without cirrhosis (0% vs. 1.2% and 1.8%, p < 0.001). Among the subset of patients with cirrhosis, risks were 4.2% (low), 6.9% (intermediate) and 27.3% (high) ( p < 0.001).

Conclusions

CHB patients with metabolic dysfunction and/or MASLD are at significant risk of HCC. The PAGE‐B score can be used to stratify HCC risk in this population, with negligible 5‐year HCC incidence in those without cirrhosis and low PAGE‐B scores. However, caution should be exercised in patients with cirrhosis in whom HCC risk remains significant even among those with a low PAGE‐B score.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularHepatitis B, ChronicLiver NeoplasmsFatty LiverHumansMaleFemaleMiddle AgedRisk FactorsAdultAgedLiver Cirrhosis

Author keywords

PAGE‐Bdiabetes mellitus type 2dyslipidemiahypertensionoverweight

Authors and institutions

  • Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, the Netherlands.
  • Institute of Liver Studies, King's College Hospital, London, UK.
  • Toronto Centre for Liver Disease, Toronto General Hospital, University of Toronto, Toronto, Canada.
  • Liver Unit, Hospital University Valle d'Hebron and CIBEREHD del INstinuto Carlos III, Barcelona, Spain.
  • Department of Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
  • Department of Internal Medicine and Infectious Diseases, University Medical Center Groningen, Groningen, the Netherlands.

ORCID profiles: Lesley A Patmore, Willem P Brouwer, Keyur Patel, Maria Buti, Milan J Sonneveld

Funding

  • Stichting voor Lever- en Maag-Darm Onderzoek
  • Gilead Sciences

Cite

APA

Patmore, L. A., Carey, I., Feld, J. J., Brouwer, W. P., Patel, K., Buti, M., Honkoop, P., Postma, D. F., Blokzijl, H., Koc, Ö. M., van Oorschot, E., Agarwal, K., van der Valk, M., Lieveld, F. I., Kilany, M., Kramer, M., de Bruijne, J., Claassen, M. A. A., Hansen, B. E., …, & Sonneveld, M. J. (2026). Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70360

Vancouver

Patmore LA, Carey I, Feld JJ, Brouwer WP, Patel K, Buti M, et al. Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70360

BibTeX
@article{Patmore2026,
  author = {Patmore, Lesley A and Carey, Ivana and Feld, Jordan J and Brouwer, Willem P and Patel, Keyur and Buti, Maria and Honkoop, Pieter and Postma, Douwe F and Blokzijl, Hans and Koc, Özgur M and van Oorschot, Eva and Agarwal, Kosh and van der Valk, Marc and Lieveld, Faydra I and Kilany, Mai and Kramer, Matthijs and de Bruijne, Joep and Claassen, Mark A A and Hansen, Bettina E and de Man, Robert A and Janssen, Harry L A and Takkenberg, R Bart and Sonneveld, Milan J},
  title = {Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70360}
}
Start for free →